{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Decitabine+and+Hiltonol",
    "query": {
      "intervention": "Decitabine and Hiltonol"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T18:24:51.773Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03358719",
      "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Blasts 30 Percent or Less of Bone Marrow Nucleated Cells",
        "Chronic Myelomonocytic Leukemia",
        "High Risk Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Refractory Anemia"
      ],
      "interventions": [
        {
          "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-03-27",
      "completion_date": "2021-08-25",
      "has_results": true,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-25T18:24:51.773Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03358719"
    },
    {
      "nct_id": "NCT01834248",
      "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Alkylating Agent-Related Acute Myeloid Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Myelodysplastic Syndrome",
        "Refractory Anemia With Excess Blasts in Transformation"
      ],
      "interventions": [
        {
          "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2013-07-30",
      "completion_date": "2016-03-21",
      "has_results": false,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-09-25T18:24:51.773Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01834248"
    },
    {
      "nct_id": "NCT02332889",
      "title": "Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gliomas",
        "Medulloblastoma",
        "Neuroectodermal Tumors, Primitive"
      ],
      "interventions": [
        {
          "name": "Vaccine (autologous dendritic cells)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Decitabine and Hiltonol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 1,
      "start_date": "2015-04",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2018-05-04",
      "last_synced_at": "2026-09-25T18:24:51.773Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02332889"
    },
    {
      "nct_id": "NCT01241162",
      "title": "Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma",
        "Ewings Sarcoma",
        "Osteogenic Sarcoma",
        "Rhabdomyosarcoma",
        "Synovial Sarcoma"
      ],
      "interventions": [
        {
          "name": "Autologous dendritic cell vaccine with adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "1 Year to 24 Years"
      },
      "enrollment_count": 19,
      "start_date": "2010-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-09-25T18:24:51.773Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01241162"
    }
  ]
}